Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Internal Medicine | Critical Care | Emergency Medicine | Nursing | Oncology | Pediatrics | Pharmacy | Journal

Back to Journal Articles

Prophylactic Therapy Reduces Bleeding in Hemophilia A

Last Updated: November 02, 2011.

 

Prophylaxis with anti-inhibitor coagulant complex cuts bleeding events versus on-demand therapy

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with severe hemophilia A, anti-inhibitor coagulant complex prophylaxis is safe and significantly reduces bleeding episodes compared with on-demand therapy, according to a study published in the Nov. 3 issue of the New England Journal of Medicine.

WEDNESDAY, Nov. 2 (HealthDay News) -- For patients with severe hemophilia A, anti-inhibitor coagulant complex (AICC) prophylaxis is safe and significantly reduces bleeding episodes compared with on-demand therapy, according to a study published in the Nov. 3 issue of the New England Journal of Medicine.

Cindy Leissinger, M.D., from Tulane University in New Orleans, and colleagues compared the safety and efficacy of six months of AICC prophylaxis versus on-demand therapy in 34 patients (older than 2 years) with severe hemophilia A, high-titer inhibitors, and prior use of bypassing agents for bleeding. In this cross-over study, AICC was administered at a target dose of 85 U per kilogram (±15 percent) prophylactically on three nonconsecutive days a week or as on-demand treatment for bleeding episodes. A three-month wash-out period separated the two treatment periods wherein patients received on-demand therapy. Of the 34 participants, 26 completed both treatment periods and were analyzed for efficacy, and 33 received at least one study drug dose and were analyzed for safety. The number of bleeding episodes during each six-month treatment period was the primary outcome.

The investigators found that prophylaxis was associated with significant decreases in bleeding episodes, hemarthroses, and target-joint bleeding (≥3 hemarthroses in a single joint during a six-month treatment period) compared with on-demand therapy (62, 61, and 72 percent, respectively). An allergic reaction to the study drug was reported for one patient.

"AICC prophylaxis at the dosage evaluated significantly and safely decreased the frequency of joint and other bleeding events in patients with severe hemophilia A and factor VIII inhibitors," the authors write.

Several authors disclosed financial relationships with pharmaceutical and health care companies, including Baxter Bioscience, which partially funded the study.

Full Text (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: Caspase 9-Induced Apoptosis Shows Promise for Cell Therapy Next: Ivacaftor Safe, Efficacious for Cystic Fibrosis

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.